MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TMDX had $65,599K increase in cash & cash equivalents over the period. $61,949K in free cash flow.

Cash Flow Overview

Change in Cash
$65,599K
Free Cash flow
$61,949K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income
24,319 60,589
Depreciation and amortization expense
6,849 12,868
Stock-based compensation expense
9,136 18,330
Non-cash interest expense and end of term accretion expense
796 1,578
Non-cash lease expense
550 997
Unrealized foreign currency transaction gains
8 1,473
Loss on disposal of fixed assets
0 -80
Accounts receivable
-24,148 6,616
Inventory
6,902 -5,717
Prepaid expenses and other current assets
5,900 -1,081
Other non-current assets
6 4
Accounts payable
2,455 -410
Accrued expenses and other current liabilities
13,141 -2,413
Deferred revenue
1,735 -192
Operating lease liabilities
-740 -1,378
Net cash provided by operating activities
69,573 88,754
Purchases of property, plant and equipment
7,624 36,113
Net cash used in investing activities
-7,624 -36,113
Proceeds from issuance of common stock upon exercise of stock options
1,816 8,831
Proceeds from issuance of common stock in connection with employee stock purchase plan
1,963 1,286
Tax withholding payments related to net settlement of restricted stock units
138 -
Net cash provided by financing activities
3,641 10,117
Effect of exchange rate changes on cash and restricted cash
9 1,167
Net increase (decrease) in cash and restricted cash
65,599 63,925
Cash and cash equivalents at beginning of period
337,150 -
Cash and cash equivalents at end of period
466,674 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

TransMedics Group, Inc. (TMDX)

TransMedics Group, Inc. (TMDX)